Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Disease
HPV vaccine effectiveness is demonstrated in new clinical and real-world data from Merck, showcasing the sustained protection of GARDASIL®9 (9-valent Human Papillomavirus [HPV] vaccine) and GARDASIL® (4-valent HPV vaccine) against HPV-related cancers and diseases. Key findings include vaccine eff...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New Era in Cardiovascular...
The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) tested three new features—regulatory roadmap and produc...